Advertisement

Heart Failure Reviews

, Volume 19, Issue 4, pp 453–470 | Cite as

BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review

  • Pasqualina L. Santaguida
  • Andrew C. Don-Wauchope
  • Mark Oremus
  • Robert McKelvie
  • Usman Ali
  • Stephen A. Hill
  • Cynthia Balion
  • Ronald A. Booth
  • Judy A. Brown
  • Amy Bustamam
  • Nazmul Sohel
  • Parminder RainaEmail author
Article

Abstract

A systematic review was undertaken to examine the evidence for B-type natriuretic peptides (BNP and NT-proBNP) as independent predictors of mortality, morbidity, or combined mortality and morbidity outcomes in persons with acute decompensated heart failure (ADHF). Electronic databases (Medline®, Embase™, AMED, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL) were searched from 1989 to June 2012. Reference lists of included articles, systematic reviews, and the gray literature were also searched. English language studies were eligible if they included subjects with ADHF and measured BNP/NT-proBNP using FDA approved assays. Standardized forms were used to select studies, extract data, and assess risk of bias. Seventy-nine studies, ranging over followup intervals from 14 days to 7 years, evaluating levels of BNP (n = 38), NT-proBNP (n = 35), or both (n = 6) were eligible. The majority of studies predicted mortality outcomes for admission BNP/NT-proBNP levels, with fewer studies evaluating serial, change from admission, or discharge levels. In general, higher levels of admission BNP or NT-proBNP predicted greater risk for all outcomes. Decreased levels post-admission predicted decreased risk. Overall, these studies were rated as having moderate risk of bias. This systematic review shows that BNP and NT-proBNP are independent predictors of mortality (all-cause and cardiovascular) in ADHF despite different cutpoints, time intervals, and prognostic models. Findings for morbidity and composite outcomes were less frequently evaluated and showed inconsistency. Further research is required to assess cutpoints for admission, serial measurements, change following admission, and discharge levels to assist clinical decision-making.

Keywords

BNP NT-proBNP Acute decompensated heart failure Prognosis Systematic review 

Notes

Acknowledgments

This manuscript is based on research conducted by the McMaster Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290 2007-10060-I). The findings and conclusions in this paper are those of the authors, who are responsible for its content, and do not necessarily represent the views of the Agency for Healthcare Research and Quality. No statement herein should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services. Parminder Raina holds a Tier 1 Canada Research Chair in Geroscience and the Raymond and Margaret Labarge Chair in Research and Knowledge Application for Optimal Aging.

Conflict of interest

Mark Oremus, Robert McKelvie, Pasqualina L. Santaguida, Usman Ali, Cynthia Balion, Stephen Hill, Judy A. Brown, Amy Bustamam, Nazmul Sohel, and Parminder Raina have no conflicts of interest or financial ties to disclose. Andrew C. Don-Wauchope has received clinical trial support from AMGEN. Ronald A. Booth has received honoraria from INOVA Diagnostics Inc. and is a member of the Health Technology Expert Review Panel of the Canadian Agency for Drugs and Technologies in Health (CADTH).

Supplementary material

10741_2014_9442_MOESM1_ESM.docx (753 kb)
Supplementary material 1 (DOCX 752 kb)

References

  1. 1.
    Balion C, Santaguida PL, Hill S, Worster A, McQueen M, Oremus M, McKelvie R, Booker L, Fagbemi J, Reichert S, Raina P (2006) Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. AHRQ, Rockville. AHRQ Publication No. 06-E014Google Scholar
  2. 2.
    Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D et al (2009) B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circ Cardiovasc Qual Outcomes 120:2177–2187. doi: 10.1161/CIRCULATIONAHA.109.884866 Google Scholar
  3. 3.
    Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330:625. doi: 10.1136/bmj.330.7492.62 PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Vesbianu D, Vesbianu C, Bernstein P, Kouides R (2008) Plasma brain natriuretic peptide—an independent predictor of mortality and rehospitalization in congestive heart failure—a meta-analysis. World Heart J 1:349–354Google Scholar
  5. 5.
    Oremus M, Raina PS, Santaguida P, Balion CM, McQueen MJ, McKelvie R et al (2008) A systematic review of BNP as a predictor of prognosis in persons with coronary artery disease. Clin Biochem 41:260–265. doi: 10.1016/j.clinbiochem.2007.09.011 PubMedCrossRefGoogle Scholar
  6. 6.
    Avellino A, Collins SP, Fermann GJ (2011) Risk stratification and short-term prognosis in acute heart failure syndromes: a review of novel biomarkers. Biomarkers 16:379–392. doi: 10.3109/1354750X.2011.574234 PubMedCrossRefGoogle Scholar
  7. 7.
    Methods guide for effectiveness and comparative effectiveness reviews (2014). Agency for Healthcare Research and Quality, Rockville. AHRQ Publication No. 10(14)-EHC063-EF. http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&mp=1&productID=318
  8. 8.
    Hayden JA, Côté P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427–437. doi: 10.7326/0003-4819-144-6-200603210-00010 PubMedCrossRefGoogle Scholar
  9. 9.
    Law KK, Yau WH, Ho HF (2010) Short-term prognostic value of the rapid b-type natriuretic peptide assay on length of hospitalisation in congestive heart failure patients presenting to an emergency department in Hong Kong: a prospective observational study. Hong Kong J Emerg Med 17:451–463Google Scholar
  10. 10.
    Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G et al (2004) Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44:1328–1333. doi: 10.1016/j.jacc.2004.06.015 PubMedCrossRefGoogle Scholar
  11. 11.
    Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F et al (2004) Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43:635–641. doi: 10.1016/j.jacc.2003.09.044 PubMedCrossRefGoogle Scholar
  12. 12.
    Aspromonte N, Feola M, Milli M, Scardovi AB, Coletta C, Carbonieri E et al (2007) Prognostic role of B-type natriuretic peptide in patients with diabetes and acute decompensated heart failure. Diabet Med 24:124–130. doi: 10.1111/j.1464-5491.2007.02070.x PubMedCrossRefGoogle Scholar
  13. 13.
    Stoiser B, Mörtl D, Hulsmann M, Berger R, Struck J, Morgenthaler NG et al (2006) Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 36:771–778. doi: 10.1111/j.1365-2362.2006.01724.x PubMedCrossRefGoogle Scholar
  14. 14.
    Cournot M, Leprince P, Destrac S, Ferriéres J (2007) Usefulness of in-hospital change in B-type natriuretic peptide levels in predicting long-term outcome in elderly patients admitted for decompensated heart failure. Am J Geriatr Cardiol 16:8–14. doi: 10.1111/j.1076-7460.2007.05297.x PubMedCrossRefGoogle Scholar
  15. 15.
    Sun T, Wang L, Zhang Y (2007) Prognostic value of B-type natriuretic peptide in patients with chronic and advanced heart failure. Intern Med J 37:168–171. doi: 10.1111/j.1445-5994.2006.01296.x PubMedCrossRefGoogle Scholar
  16. 16.
    Gegenhuber A, Struck J, Dieplinger B, Poelz W, Pacher R, Morgenthaler NG et al (2007) Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13:42–49. doi: 10.1016/j.cardfail.2006.09.004 PubMedCrossRefGoogle Scholar
  17. 17.
    Kellett J (2006) Prediction of mortality of patients with suspected heart failure by brain natriuretic peptide concentrations > 100 pg/ml: comparison of a clinical model with brain natriuretic peptide concentrations. Heart 92:1512–1513. doi: 10.1136/hrt.2005.069286 PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Valle R, Aspromonte N, Feola M, Milli M, Canali C, Giovinazzo P et al (2005) B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 11:498–503. doi: 10.1016/j.cardfail.2005.05.002 PubMedCrossRefGoogle Scholar
  19. 19.
    Dokainish H, Zoghbi WA, Lakkis NM, Ambriz E, Patel R, Quinones MA et al (2005) Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol 45:1223–1226. doi: 10.1016/j.jacc.2005.01.025 PubMedCrossRefGoogle Scholar
  20. 20.
    Di Somma S, Magrini L, Pittoni V, Marino R, Mastrantuono A, Ferri E et al (2010) In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care 14:R116. doi: 10.1186/cc9067 PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Zairis MN, Tsiaousis GZ, Georgilas AT, Makrygiannis SS, Adamopoulou EN, Handanis SM et al (2010) Multimarker strategy for the prediction of 31 days cardiac death in patients with acutely decompensated chronic heart failure. Int J Cardiol 141:284–290. doi: 10.1016/j.ijcard.2008.12.017 PubMedCrossRefGoogle Scholar
  22. 22.
    Reichlin T, Socrates T, Egli P, Potocki M, Breidthardt T, Arenja N et al (2010) Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem 56:944–951. doi: 10.1373/clinchem.2009.142257 PubMedCrossRefGoogle Scholar
  23. 23.
    Nahum J, Bensaid A, Dussault C, Macron L, Clemence D, Bouhemad B et al (2010) Impact of longitudinal myocardial deformation on the prognosis of chronic heart failure patients. Circ Heart Fail 3:249–256. doi: 10.1161/?CIRCIMAGING.109.910893 Google Scholar
  24. 24.
    Faggiano P, Valle R, Aspromonte N, D’Aloia A, Di Tano G, Barro S et al (2010) How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification. Int J Cardiol 140:88–94. doi: 10.1016/j.ijcard.2008.11.020 PubMedCrossRefGoogle Scholar
  25. 25.
    Farmakis D, Parissis JT, Bistola V, Paraskevaidis IA, Iliodromitis EK, Filippatos G et al (2010) Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. Int J Cardiol 139:75–79. doi: 10.1016/j.ijcard.2008.10.003 PubMedCrossRefGoogle Scholar
  26. 26.
    Neuhold S, Huelsmann M, Strunk G, Struck J, Adlbrecht C, Gouya G et al (2010) Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem 56:121–126. doi: 10.1373/clinchem.2009.125856 PubMedCrossRefGoogle Scholar
  27. 27.
    Dunlay SM, Gerber Y, Weston SA, Killian JM, Redfield MM, Roger VL (2009) Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail 2:393–400. doi: 10.1161/CIRCHEARTFAILURE.109.849299 PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Singer AJ, Birkhahn RH, Guss D, Chandra A, Miller CD, Tiffany B et al (2009) Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management. Circ Heart Fail 2:287–293. doi: 10.1161/CIRCHEARTFAILURE.108.826685 PubMedCrossRefGoogle Scholar
  29. 29.
    Parissis JT, Farmakis D, Nikolaou M, Birmpa D, Bistola V, Paraskevaidis I et al (2009) Plasma B-type natriuretic peptide and anti-inflammatory cytokine interleukin-10 levels predict adverse clinical outcome in chronic heart failure patients with depressive symptoms: a 1-year follow-up study. Eur J Heart Fail 11:967–972. doi: 10.1093/eurjhf/hfp125 PubMedCrossRefGoogle Scholar
  30. 30.
    Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A (2009) Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 53:2343–2348. doi: 10.1016/j.jacc.2009.02.058 PubMedCrossRefGoogle Scholar
  31. 31.
    Dhaliwal AS, Deswal A, Pritchett A, Aguilar D, Kar B, Souchek J et al (2009) Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail 15:293–299. doi: 10.1016/j.cardfail.2008 PubMedCrossRefGoogle Scholar
  32. 32.
    Núñez J, Núñez E, Robles R, Bodi V, Sanchis J, Carratalá A et al (2008) Prognostic value of brain natriuretic peptide in acute heart failure: mortality and hospital readmission. Rev Esp Cardiol 61:1332–1337. doi: 10.1016/S1885-5857(09)60062-1 CrossRefGoogle Scholar
  33. 33.
    Feola M, Aspromonte N, Milani L, Bobbio M, Bardellotto S, Barro S et al (2008) Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern. J Card Fail 14:420–425. doi: 10.1016/j.cardfail.2008.01.013 PubMedCrossRefGoogle Scholar
  34. 34.
    Cournot M, Mourre F, Castel F, Ferriéres J, Destrac S (2008) Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure. Am Heart J 155:986–991. doi: 10.1016/j.ahj.2008.01.011 PubMedCrossRefGoogle Scholar
  35. 35.
    Valle R, Aspromonte N, Carbonieri E, D’Eri A, Feola M, Giovinazzo P et al (2008) Fall in readmission rate for heart failure after implementation of B-type natriuretic peptide testing for discharge decision: a retrospective study. Int J Cardiol 126:400–406. doi: 10.1016/j.ijcard.2006.03.097 PubMedCrossRefGoogle Scholar
  36. 36.
    Parissis JT, Nikolaou M, Farmakis D, Bistola V, Paraskevaidis IA, Adamopoulos S et al (2008) Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure. Heart 94:585–589. doi: 10.1136/hrt.2007.117390 PubMedCrossRefGoogle Scholar
  37. 37.
    Valle R, Aspromonte N, Giovinazzo P, Carbonieri E, Chiatto M, Di Tano G et al (2008) B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. J Card Fail 14:219–224. doi: 10.1016/j.cardfail.2007.10.009 PubMedCrossRefGoogle Scholar
  38. 38.
    Dieplinger B, Gegenhuber A, Poelz W, Haltmayer M, Mueller T (2009) Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biochem 42:1190–1193. doi: 10.1016/j.clinbiochem.2009.02.023 PubMedCrossRefGoogle Scholar
  39. 39.
    Núñez J, Sanchis J, Bodi V, Fonarow GC, Núñez E, Bertomeu-Gonzalez V et al (2010) Improvement in risk stratification with the combination of the tumour marker antigen carbohydrate 125 and brain natriuretic peptide in patients with acute heart failure. Eur Heart J 31:1752–1763. doi: 10.1093/eurheartj/ehq142 PubMedCrossRefGoogle Scholar
  40. 40.
    Pimenta J, Paulo C, Mascarenhas J, Gomes A, Azevedo A, Rocha-Gonçalves F et al (2010) BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. Int J Cardiol 145:209–214. doi: 10.1016/j.ijcard.2009.08.001 PubMedCrossRefGoogle Scholar
  41. 41.
    Xue Y, Clopton P, Peacock WF, Maisel AS (2011) Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail 13:37–42. doi: 10.1093/eurjhf/hfq210 PubMedCrossRefGoogle Scholar
  42. 42.
    Rychli K, Richter B, Hohensinner PJ, Kariem Mahdy A, Neuhold S, Zorn G et al (2011) Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure. Heart 97:1158–1163. doi: 10.1136/hrt.2010.220228 PubMedCrossRefGoogle Scholar
  43. 43.
    Arques SR (2011) Usefulness of serum albumin and serum total cholesterol in the prediction of hospital death in older patients with severe, acute heart failure. Arch Cardiovasc Dis 104:502–508. doi: 10.1016/j.acvd.2011.06.003 PubMedCrossRefGoogle Scholar
  44. 44.
    Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ et al (2011) Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes 4:389–398. doi: 10.1161/CIRCOUTCOMES.110.958009 PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Coyne JC, Jaarsma T, Luttik ML, van Sonderen E, van Veldhuisen DJ, Sanderman R (2011) Lack of prognostic value of type D personality for mortality in a large sample of heart failure patients. Psychosom Med 73:557–562. doi: 10.1097/PSY.0b013e318227ac75 PubMedCrossRefGoogle Scholar
  46. 46.
    Maisel AS, Mueller C, Fitzgerald R, Brikhan R, Hiestand BC, Iqbal N et al (2011) Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 13:846–851. doi: 10.1093/eurjhf/hfr087 PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Arenja N, Reichlin T, Drexler B, Oshima S, Denhaerynck K, Haaf P et al (2012) Sensitive cardiac troponin in the diagnosis and risk stratification of acute heart failure. J Intern Med 271:598–607. doi: 10.1111/j.1365-2796.2011.02469.x PubMedCrossRefGoogle Scholar
  48. 48.
    Sakhuja R, Green S, Oestreicher EM, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB et al (2007) Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure. Clin Chem 53:412–420. doi: 10.1373/clinchem.2006.074047 PubMedCrossRefGoogle Scholar
  49. 49.
    Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P et al (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55:2062–2076. doi: 10.1016/j.jacc.2010.02.025 PubMedCrossRefGoogle Scholar
  50. 50.
    Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J et al (2008) Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 14:732–738. doi: 10.1016/j.cardfail.2008.06.415 PubMedCrossRefGoogle Scholar
  51. 51.
    Noveanu M, Breidthardt T, Potocki M, Reichlin T, Twerenbold R, Uthoff H et al (2011) Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure. Crit Care 15:R1. doi: 10.1186/cc9398 PubMedCentralPubMedCrossRefGoogle Scholar
  52. 52.
    Rehman SU, Mueller T, Januzzi J (2008) Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol 52:1458–1465. doi: 10.1016/j.jacc.2008.07.042 PubMedCrossRefGoogle Scholar
  53. 53.
    Peacock WF, Nowak R, Christenson R, DiSomma S, Neath SX, Hartmann O et al (2011) Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med 18:947–958. doi: 10.1111/j.1553-2712.2011.01150.x PubMedCrossRefGoogle Scholar
  54. 54.
    Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A (2004) N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circ Cardiovasc Qual Outcomes 110:2168–2174. doi: 10.1161/01.CIR.0000144310.04433.BE Google Scholar
  55. 55.
    Baggish AL, van Kimmenade R, Bayes-Genis A, Davis M, Lainchbury JG, Frampton C et al (2007) Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta 381:145–150. doi: 10.1016/j.cca.2007.03.010 PubMedCrossRefGoogle Scholar
  56. 56.
    Bettencourt P, Azevedo A, Fonseca L, Araujo JP, Ferreira S, Almeida R et al (2007) Prognosis of decompensated heart failure patients with preserved systolic function is predicted by NT-proBNP variations during hospitalization. Int J Cardiol 117:75–79. doi: 10.1016/j.ijcard.2006.06.004 PubMedCrossRefGoogle Scholar
  57. 57.
    Perna ER, Macin SM, Cimbaro Canella JP, Szyszko A, Franciosi V, Vargas MW et al (2006) Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure. J Heart Lung Transpl 25:1230–1240. doi: 10.1016/j.healun.2006.08.004 CrossRefGoogle Scholar
  58. 58.
    van Kimmenade RR, Januzzi JL Jr, Baggish AL, Lainchbury JG, Bayes-Genis A, Richards AM et al (2006) Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? J Am Coll Cardiol 48:1621–1627. doi: 10.1016/j.jacc.2006.06.056 PubMedCrossRefGoogle Scholar
  59. 59.
    van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF et al (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48:1217–1224. doi: 10.1016/j.jacc.2006.03.061 PubMedCrossRefGoogle Scholar
  60. 60.
    Marcucci R, Gori AM, Giannotti F, Baldi M, Verdiani V, Del Pace S et al (2006) Markers of hypercoagulability and inflammation predict mortality in patients with heart failure. J Thromb Haemostasis 4:1017–1022. doi: 10.1111/j.1538-7836.2006.01916.x CrossRefGoogle Scholar
  61. 61.
    Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordóñnez-Llanos J, Santalo-Bel M et al (2006) NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 27:330–337. doi: 10.1093/eurheartj/ehi631 PubMedCrossRefGoogle Scholar
  62. 62.
    Bayés-Genis A, Lopez L, Zapico E, Cotes C, Santaló M, Ordóñnez-Llanos J et al (2005) NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality. J Card Fail 11:S3–S8. doi: 10.1016/j.cardfail.2005.04.006 PubMedCrossRefGoogle Scholar
  63. 63.
    Bayes-Genis A, Pascual-Figal D, Fabregat J, Domingo M, Planas F, Casas T et al (2007) Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Cardiol 120:338–343. doi: 10.1016/j.ijcard.2006.10.009 PubMedCrossRefGoogle Scholar
  64. 64.
    Ferreira S, Almeida R, Guerrero H, Lourenco-Ferreira S, Fonseca L, Rocha R et al (2007) Prognosis of decompensated heart failure: role of NT-proBNP. Rev Port Cardiol 26:535–545PubMedGoogle Scholar
  65. 65.
    Pimenta JM, Almeida R, Araújo JP, Azevedo A, Friões F, Rocha-Gonçalves F et al (2007) Amino terminal B-type natriuretic peptide, renal function, and prognosis in acute heart failure: a hospital cohort study. J Card Fail 13:275–280. doi: 10.1016/j.cardfail.2007.01.001 PubMedCrossRefGoogle Scholar
  66. 66.
    Siswanto BB, Sunanto Munawar M, Kusmana D, Hanafiah A, Waspadji S et al (2006) Predictor of mortality and rehospitalization of acute decompensated heart failure at six months follow up. Crit Care Shock 9:61–67Google Scholar
  67. 67.
    Park HS, Kim H, Sohn JH, Shin HW, Cho YK, Yoon HJ et al (2010) Combination of uric acid and NT-ProBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure. Korean J Intern Med 25:253–259. doi: 10.3904/kjim.2010.25.3.253 PubMedCentralPubMedCrossRefGoogle Scholar
  68. 68.
    Davutoglu V, Yildirim C, Kucukaslan H, Yuce M, Sari I, Tarakcioglu M et al (2010) Prognostic value of pleural effusion, CA-125 and NT-proBNP in patients with acute decompensated heart failure. Kardiol Pol 68:771–778PubMedGoogle Scholar
  69. 69.
    Dini FL, Buralli S, Bajraktari G, Elezi S, Duranti E, Metelli MR et al (2010) Plasma matrix metalloproteinase-9 better predicts outcome than N-terminal protype-B natriuretic peptide in patients with systolic heart failure and a high prevalence of coronary artery disease. Biomed Pharmacother 64:339–342. doi: 10.1016/j.biopha.2009.09.008 PubMedCrossRefGoogle Scholar
  70. 70.
    Mohammed AA, van Kimmenade RR, Richards M, Bayes-Genis A, Pinto Y, Moore SA et al (2010) Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. Circ Heart Fail 3:354–361. doi: 10.1161/CIRCHEARTFAILURE.109.915280 PubMedCrossRefGoogle Scholar
  71. 71.
    Baggish AL, van Kimmenade RR, Pinto Y, Richards AM, Lainchbury J, Bayes-Genis A et al (2010) New York Heart Association class versus amino-terminal pro-B-type natriuretic peptide for acute heart failure prognosis. Biomarkers 15:307–314. doi: 10.3109/13547501003632580 PubMedCrossRefGoogle Scholar
  72. 72.
    Lourenco P, Azevedo A, Araújo JP, Bettencourt P (2009) Natriuretic peptide system is not exhausted in severe heart failure. J Cardiovasc Med (Hagerstown) 10:39–43. doi: 10.2459/JCM.0b013e328319679f CrossRefGoogle Scholar
  73. 73.
    Manzano-Fernández S, Boronat-Garcia M, Albaladejo-Otón MD, Pastor P, Garrido IP, Pastor-Pérez FJ et al (2009) Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol 103:1753–1759. doi: 10.1016/j.amjcard.2009.02.029 PubMedCrossRefGoogle Scholar
  74. 74.
    Kubler P, Jankowska EA, Majda J, Reczuch K, Banasiak W, Ponikowski P (2008) Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome. Int J Cardiol 129:373–378. doi: 10.1016/j.ijcard.2007.07.126 PubMedCrossRefGoogle Scholar
  75. 75.
    Paul B, Soon KH, Dunne J, De Pasquale CG (2008) Diagnostic and prognostic significance of plasma N-terminal-pro-brain natriuretic peptide in decompensated heart failure with preserved ejection fraction. Heart Lung Circ 17:497–501. doi: 10.1016/j.hlc.2008.06.001 PubMedCrossRefGoogle Scholar
  76. 76.
    Verdiani V, Ognibene A, Rutili MS, Lombardo C, Bacci F, Terreni A et al (2008) NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients. J Cardiovasc Med (Hagerstown) 9:694–699. doi: 10.2459/JCM.0b013e3282f447ae CrossRefGoogle Scholar
  77. 77.
    Andersson SE, Edvinsson ML, Bjõrk J, Edvinsson L (2008) High NT-proBNP is a strong predictor of outcome in elderly heart failure patients. Am J Geriatr Cardiol 17:13–20. doi: 10.1111/j.1076-7460.2007.06674.x PubMedCrossRefGoogle Scholar
  78. 78.
    Petretta M, Scopacasa F, Fontanella L, Carlomagno A, Baldissara M, de Simone A et al (2007) Prognostic value of reduced kidney function and anemia in patients with chronic heart failure. J Cardiovasc Med (Hagerstown) 8:909–916. doi: 10.2459/JCM.0b013e32801464b6 CrossRefGoogle Scholar
  79. 79.
    Metra M, Nodari S, Parrinello G, Specchia C, Brentana L, Rocca P et al (2007) The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T. Eur J Heart Fail 9:776–786. doi: 10.1016/j.ejheart.2007.05.007 PubMedCrossRefGoogle Scholar
  80. 80.
    Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K et al (2007) Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28:1841–1847. doi: 10.1093/eurheartj/ehl507 PubMedCrossRefGoogle Scholar
  81. 81.
    Lüers C, Schmidt A, Wachter R, Fritzsche F, Sutcliffe A, Kleta S et al (2010) Serial NT-proBNP measurements for risk stratification of patients with decompensated heart failure. Herz 35:488–496. doi: 10.1007/s00059-010-3377-4 PubMedCrossRefGoogle Scholar
  82. 82.
    Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, Martinez-Marcos FJ, Camacho-Vazquez C, Ruiz-Frutos C et al (2011) Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail 17:31–38. doi: 10.1016/j.cardfail.2010.07.248 PubMedCrossRefGoogle Scholar
  83. 83.
    Pascual-Figal DA, Manzano-Fernández S, Boronat M, Casas T, Garrido IP, Bonaque JC et al (2011) Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 13:718–725. doi: 10.1093/eurjhf/hfr047 PubMedCrossRefGoogle Scholar
  84. 84.
    Ho SJ, Feng AN, Lee LN, Chen JW, Lin SJ (2011) Predictive value of predischarge spectral tissue doppler echocardiography and n-terminal pro-B-type natriuretic peptide in patients hospitalized with acute heart failure. Echocardiography 28:303–310. doi: 10.1111/j.1540-8175.2010.01322.x PubMedCrossRefGoogle Scholar
  85. 85.
    Michtalik HJ, Yeh HC, Campbell CY, Haq N, Park H, Clarke W et al (2011) Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Am J Cardiol 107:1191–1195. doi: 10.1016/j.amjcard.2010.12.018 PubMedCrossRefGoogle Scholar
  86. 86.
    Korewicki J, Leszek P, Zielinski T, Rywik T, Piotrowski W, Kurjata P et al (2012) Severe chronic heart failure in patients considered for heart transplantation in Poland. Cardiol J 19:36–44. doi: 10.5603/CJ.2012.0007 PubMedCrossRefGoogle Scholar
  87. 87.
    Krackhardt F, Düngen HD, Trippel TD, Inkrot S, Tscholl V, Schlattmann P et al (2011) N-terminal pro-B-type natriuretic peptide and long-term mortality in non-ischemic cardiomyopathy. Wien Klin Wochenschr 123:738–742. doi: 10.1007/s00508-011-0092-y PubMedCrossRefGoogle Scholar
  88. 88.
    Harutyunyan M, Christiansen M, Johansen JS, Køber L, Torp-Petersen C, Kastrup J (2012) The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure. Immunobiology 217:652–656. doi: 10.1016/j.imbio.2011.11.003 PubMedCrossRefGoogle Scholar
  89. 89.
    Kalil AC, Mattei J, Florescu DF, Sun J, Kalil RS (2010) Recommendations for the assessment and reporting of multivariable logistic regression in the transplantation literature. Am J Transpl 10:1686–1694. doi: 10.1111/j.1600-6143.2010.03141.x CrossRefGoogle Scholar
  90. 90.
    Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. York, UK: CRD, University of York; 2009. http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Pasqualina L. Santaguida
    • 1
  • Andrew C. Don-Wauchope
    • 2
  • Mark Oremus
    • 1
  • Robert McKelvie
    • 3
  • Usman Ali
    • 1
  • Stephen A. Hill
    • 2
  • Cynthia Balion
    • 2
  • Ronald A. Booth
    • 4
  • Judy A. Brown
    • 1
  • Amy Bustamam
    • 1
  • Nazmul Sohel
    • 1
  • Parminder Raina
    • 1
    Email author
  1. 1.Department of Epidemiology and BiostatisticsMcMaster UniversityHamiltonCanada
  2. 2.Department of Pathology and Molecular MedicineMcMaster UniversityHamiltonCanada
  3. 3.Department of MedicineMcMaster UniversityHamiltonCanada
  4. 4.Department of Pathology and Laboratory MedicineUniversity of OttawaOttawaCanada

Personalised recommendations